Agenus Inc (AGEN) - Total Assets
Based on the latest financial reports, Agenus Inc (AGEN) holds total assets worth $186.46 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore debt repayment capacity of Agenus Inc to assess how comfortably operating cash covers total debt obligations.
Agenus Inc - Total Assets Trend (1999–2025)
This chart illustrates how Agenus Inc's total assets have evolved over time, based on quarterly financial data. See AGEN book value for net asset value and shareholders' equity analysis.
Agenus Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Agenus Inc's total assets of $186.46 Million consist of 58.8% current assets and 41.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 1.3% |
| Accounts Receivable | $1.83 Million | 0.8% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $3.04 Million | 1.3% |
| Goodwill | $24.09 Million | 10.6% |
Asset Composition Trend (1999–2025)
This chart illustrates how Agenus Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Agenus Inc market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Agenus Inc's current assets represent 58.8% of total assets in 2025, a decrease from 85.2% in 1999.
- Cash Position: Cash and equivalents constituted 1.3% of total assets in 2025, down from 82.9% in 1999.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 11.0% of total assets, an increase from 0.0% in 1999.
- Asset Diversification: The largest asset category is goodwill at 10.6% of total assets.
Agenus Inc Competitors by Total Assets
Key competitors of Agenus Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
Agenus Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.38 | 0.11 | 0.55 |
| Quick Ratio | 0.38 | 0.11 | 0.47 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-153.95 Million | $-185.17 Million | $-75.90 Million |
Agenus Inc - Advanced Valuation Insights
This section examines the relationship between Agenus Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 218.61 |
| Latest Market Cap to Assets Ratio | 0.62 |
| Asset Growth Rate (YoY) | 0.2% |
| Total Assets | $226.80 Million |
| Market Capitalization | $141.17 Million USD |
Valuation Analysis
Below Book Valuation: The market values Agenus Inc's assets below their book value (0.62x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Agenus Inc's assets grew by 0.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Agenus Inc (1999–2025)
The table below shows the annual total assets of Agenus Inc from 1999 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $226.80 Million | +0.23% |
| 2024-12-31 | $226.27 Million | -27.92% |
| 2023-12-31 | $313.91 Million | -24.09% |
| 2022-12-31 | $413.56 Million | -11.25% |
| 2021-12-31 | $465.96 Million | +117.22% |
| 2020-12-31 | $214.51 Million | +38.10% |
| 2019-12-31 | $155.34 Million | +13.88% |
| 2018-12-31 | $136.40 Million | -1.45% |
| 2017-12-31 | $138.40 Million | -11.84% |
| 2016-12-31 | $156.99 Million | -35.19% |
| 2015-12-31 | $242.23 Million | +225.02% |
| 2014-12-31 | $74.53 Million | +113.94% |
| 2013-12-31 | $34.84 Million | +0.47% |
| 2012-12-31 | $34.67 Million | +75.05% |
| 2011-12-31 | $19.81 Million | -35.91% |
| 2010-12-31 | $30.91 Million | -32.63% |
| 2009-12-31 | $45.87 Million | -19.44% |
| 2008-12-31 | $56.95 Million | +27.86% |
| 2007-12-31 | $44.54 Million | -38.95% |
| 2006-12-31 | $72.95 Million | -29.96% |
| 2005-12-31 | $104.15 Million | -21.73% |
| 2004-12-31 | $133.06 Million | -5.01% |
| 2003-12-31 | $140.08 Million | +57.28% |
| 2002-12-31 | $89.06 Million | -4.79% |
| 2001-12-31 | $93.55 Million | -26.90% |
| 2000-12-31 | $127.97 Million | +128.51% |
| 1999-12-31 | $56.00 Million | -- |
About Agenus Inc
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvan… Read more